Study S000837

A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01558271
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 492
Start: 2012-03
Primary completion: 2013-10
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:LY2189265; DRUG:Placebo; DRUG:Liraglutide
Results posted: TRUE
Secondary identifiers: OTHER:H9X-JE-GBDP

Registered primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks [Baseline, 26 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021631	Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes. Iwamoto N, Diabetes therapy : research, treatment and education of diabetes and related disorders	2018	Other trial	PMID 29264713 DOI	cites ClinicalTrials.gov:NCT01558271; registry reference DERIVED:29264713
R0021009	Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Suzuki S, Health and quality of life outcomes	2017	Randomized trial	PMID 28606095 DOI	cites ClinicalTrials.gov:NCT01558271; registry reference DERIVED:28606095